Journal: International Journal of Clinical and Experimental Medicine

Article Title: Prognostic and clinical significance of STAT3 and MMP9 in patients with gastric cancer: a meta-analysis of a Chinese cohort

doi:

Figure Lengend Snippet: Ongoing studies evaluating anti-STAT3 and anti–MMP9 therapeutic strategies

Article Snippet: Anderson Cancer Center Advanced Cancer Solid Tumor; phase 1 OPB-31121 {"type":"clinical-trial","attrs":{"text":"NCT00105950","term_id":"NCT00105950"}} NCT00105950 GlaxoSmithKline Neoplasms, Breast; phase 2 Lapatinib {"type":"clinical-trial","attrs":{"text":"NCT00655499","term_id":"NCT00655499"}} NCT00655499 Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) Colorectal Cancer - {"type":"clinical-trial","attrs":{"text":"NCT00113217","term_id":"NCT00113217"}} NCT00113217 M.D.

Techniques:

Journal: Cancers

Article Title: YY1 Oligomerization Is Regulated by Its OPB Domain and Competes with Its Regulation of Oncoproteins

doi: 10.3390/cancers14071611

Figure Lengend Snippet: Mapping YY1 binding domains involved in its intermolecular interactions by the surface plasmon resonance (SPR) analysis. ( A ) Schematic diagrams of the domain structures of YY1 protein. “Acidic” represents a region enriched with aspartic and glutamic acids, and “ED” and “G” depict regions containing a glutamic/aspartic acid cluster and a glycine cluster, respectively. “His” indicates a region consisting of 11 consecutive histidines, and “GA” and “GK” represent glycine/alanine- and glycine/lysine-enriched regions, respectively; OPB: oncoprotein binding; the Spacer region and each C2H2-type Zinc finger domain are also denoted. ( B , D ) Diagrams of His-tagged (×6) YY1 wt and mutants used to map domains responsible for YY1 intermolecular interactions. ( C , E ) Evaluation of YY1 intermolecular interactions using the SPR analysis. As the immobile phase, purified His×6-YY1 wt ( C ) and its mutant (1–226) ( E ) were individually conjugated to the CM5 chip (GE healthcare). As the mobile phase, purified His×6-YY1 wt and its mutant proteins were serially diluted into concentrations of 62.5, 125, 250, 500 and 1000 nM for injection. The samples individually flowed over the chip channels with different conjugates, and the response units (RU) were received from each single cycle. The binding kinetics were analyzed with the Biacore T200 Evaluation software, version 2.0. The results are displayed with time (s) versus and the RU values.

Article Snippet: The OPB and YPB (YY1 protein binding domain in the human EZH2 protein) peptides, as we previously reported [ ], were synthesized by the ChinaPeptides Co., Ltd. (Shanghai, China).

Techniques: Binding Assay, SPR Assay, Purification, Mutagenesis, Injection, Software

Journal: Cancers

Article Title: YY1 Oligomerization Is Regulated by Its OPB Domain and Competes with Its Regulation of Oncoproteins

doi: 10.3390/cancers14071611

Figure Lengend Snippet: Identification of the binding sites responsible for YY1 dimerization by co-immunoprecipitation (co-IP). ( A ) Diagrams of HA- and Flag-tagged YY1 wt and its mutant proteins used for co-IP studies. ( B , C ) Co-IP studies to determine the binding sites responsible for YY1 dimerization. HA-YY1 wt ( B ) or its ΔZF mutant ( C ) expression plasmid was individually cotransfected with Flag-EGFP-YY1 wt and mutant expression vectors, as well as an empty vector (EV). Cell lysates were co-IPed by a Flag antibody, and HA and Flag antibodies were used in Western blot analyses. ( D ) Schematic diagram of a predicted YY1 dimerization mode. ( E ) Effects of the OPB on intermolecular interaction of YY1. Different amounts of mCherry-cont, mCherry-OPB and mCherry plasmids were individually cotransfected with Flag-EGFP-YY1(ΔZF) and HA-YY1(ΔZF) expression vectors, followed by co-IP of the Flag antibody. HA, mCherry and Flag antibodies were used in Western blot analyses.

Article Snippet: The OPB and YPB (YY1 protein binding domain in the human EZH2 protein) peptides, as we previously reported [ ], were synthesized by the ChinaPeptides Co., Ltd. (Shanghai, China).

Techniques: Binding Assay, Immunoprecipitation, Co-Immunoprecipitation Assay, Mutagenesis, Expressing, Plasmid Preparation, Western Blot

Journal: Cancers

Article Title: YY1 Oligomerization Is Regulated by Its OPB Domain and Competes with Its Regulation of Oncoproteins

doi: 10.3390/cancers14071611

Figure Lengend Snippet: Characterization of key amino acids in charge of YY1 intermolecular interaction. ( A ) Diagrams of OPB point mutations to determine key hydrophobic amino acids involved in intermolecular interactions among YY1 molecules. ( B ) Evaluation of YY1 interaction with OPB wt and mutants. Plasmids of Flag-EGFP-OPB wt and mutants were individually cotransfected with the HA-YY1 expression vector, followed by IP of the Flag antibody and Western blot analyses using labeled antibodies. ( C ) Examination of the effects of OPB wt and mutants on YY1 intermolecular interaction. Plasmids of mCherry-OPB wt, mutants, and cont were individually cotransfected with Flag-YY1(ΔZF) and HA-YY1(ΔZF), followed by IP using the Flag antibody and Western blot analyses using labeled antibodies. ( D ) Evaluation of the interaction between YY1 and YY1 with wt or mutated OPB sequence. Plasmids of Flag-EGFP-YY1(wt) and OPB mutants were individually cotransfected with HA-YY1(ΔZF), followed by IP using the Flag antibody and Western blot analysis using labeled antibodies. ( E ) Native polyacrylamide gel electrophoresis (PAGE) to evaluate the effects of OPB wt and mutants on YY1 intermolecular interactions. Purified His×6-YY1(wt) and (ΔZF) proteins with OPB of wt, 3A or F219A sequences were analyzed by a 10% native PAGE. The red arrow heads denote the oligomerization of YY1 proteins. ( F ) IP studies to examine the binding protein patterns by OPB wt and mutants. HeLa cells were individually transfected by Flag-EGFP-OPB wt, different OPB mutants, YPB, cont and no insert vectors, followed by IP using the Flag antibody, resolved by native gels or SDS-containing gel and analyzed by Western blot using the Flag antibody. ( G ) Circular dichroism spectroscopy of purified YY1 and its mutants. Purified His×6-YY1(wt) and (ΔZF) proteins (0.05 mg/mL) with wt or mutated OPB domain were individually scanned between the wavelengths from 190 to 280 nm at 20 °C. The data were analyzed by the GraphPad Prism 5.0 software. ( H ) The sequences of the synthetic OPB, YPB and Cont peptides. TAT: a cell-penetrating peptide (CPP) derived from human immunodeficiency virus. ( I ) Examination of the effects of OPB and YPB peptides on YY1 oligomerization. Purified His×6-YY1(ΔZF) protein (6.5 µg, or 140 pmol) was mixed with synthetic OPB, YPB and Cont peptides with a serial molar ratio of 1:1, 1:2, 1:3 and 1:4, and incubated at 4 °C for 2 h, followed by the analysis of 10% native PAGE.

Article Snippet: The OPB and YPB (YY1 protein binding domain in the human EZH2 protein) peptides, as we previously reported [ ], were synthesized by the ChinaPeptides Co., Ltd. (Shanghai, China).

Techniques: Expressing, Plasmid Preparation, Western Blot, Labeling, Sequencing, Polyacrylamide Gel Electrophoresis, Purification, Clear Native PAGE, Binding Assay, Transfection, Circular Dichroism, Spectroscopy, Software, Derivative Assay, Virus, Incubation

Journal: Cancers

Article Title: YY1 Oligomerization Is Regulated by Its OPB Domain and Competes with Its Regulation of Oncoproteins

doi: 10.3390/cancers14071611

Figure Lengend Snippet: Effects of the OPB mutations on cell proliferation and migration of breast cancer cells. ( A – D ) Effects of ectopic expression of Flag-YY1 wt and its OPB mutants on the proliferation of breast cancer cells. MDA-MB-231 cells carrying a TET-inducible shYY1 targeting the YY1 mRNA 3′-UTR cultured in doxycycline (DOX)-containing medium ( A ), or MCF-7 cells infected by lentivirus carrying the same shYY1 ( C ), were infected by lentivirus expressing Flag-YY1 wt and mutants, followed by WST-1 assay, to determine cell proliferation. Endogenous YY1 knockdown and ectopic expression of YY1 wt and mutants in MDA-MB-231 and MCF-7 cells are shown in ( B , D ), respectively. ( E , F ) Scratch assays to test the effects of YY1 mutants on breast cell migration. Endogenous YY1 knockdown and ectopic YY1 expression in MDA-MB-231 ( E ) and MCF-7 ( F ) cells carried out as described in ( A – D ). Images were captured when scratches were just made on the plates of overnight cultured cells and after 48 h of culture in the presence of 1.0 µM of Mitomycin C. The quantitation of cell migration is shown at the right panels. Data represent the mean ± S.D., n.s.: no significance, * p < 0.05, ** p < 0.01 and *** p < 0.001.

Article Snippet: The OPB and YPB (YY1 protein binding domain in the human EZH2 protein) peptides, as we previously reported [ ], were synthesized by the ChinaPeptides Co., Ltd. (Shanghai, China).

Techniques: Migration, Expressing, Cell Culture, Infection, WST-1 Assay, Knockdown, Quantitation Assay

Journal: Cancers

Article Title: YY1 Oligomerization Is Regulated by Its OPB Domain and Competes with Its Regulation of Oncoproteins

doi: 10.3390/cancers14071611

Figure Lengend Snippet: Evaluation of the effects of OPB mutations on YY1 interaction with oncoproteins. ( A , B ) Examination of the interaction between YY1 OPB mutants and EZH2. In A, GST and GST-EZH2(465–519) were individually incubated with purified His×6-YY1 wt, 3A and F219A mutants, followed by extensive wash and Western blot analyses using a His-tag antibody. The input of GST and GST-EZH2(465–519) is shown at the lower panel. In ( B ), plasmids of Flag-EGFP-YY1 wt, 3A and F219A were individually transfected into HeLa cells, followed by IP using the Flag antibody and Western blot analyses using an EZH2 antibody. Direct Western blot analyses were conducted using the antibodies as labeled. ( C , D ) Examination of the interaction of YY1 OPB mutants with AKT and MDM2. Flag-EGFP-YY1 plasmid was cotransfected with HA-AKT ( C ) or HA-MDM2 ( D ) into HeLa cells, followed by IP using the Flag antibody and Western blot analyses using an HA antibody. Direct Western blot analyses were conducted using the antibodies as labeled. Original images of all Western blot data are available in .

Article Snippet: The OPB and YPB (YY1 protein binding domain in the human EZH2 protein) peptides, as we previously reported [ ], were synthesized by the ChinaPeptides Co., Ltd. (Shanghai, China).

Techniques: Incubation, Purification, Western Blot, Transfection, Labeling, Plasmid Preparation

Journal: Cancers

Article Title: YY1 Oligomerization Is Regulated by Its OPB Domain and Competes with Its Regulation of Oncoproteins

doi: 10.3390/cancers14071611

Figure Lengend Snippet: A schematic model of competitive processes between YY1 oligomerization and its interactions with different oncoproteins. In the nucleus, YY1 oligomers may activate target gene expression through facilitating enhancer formation, but may not be able to bind the oncoproteins. As monomers, YY1 interacts with EZH2, AKT and MDM2 in either the nucleus or cytoplasm to promote their oncogenic activities, including suppressing tumor suppressive genes, stimulating proliferative signaling pathways, and enhancing p53 ubiquitination and degradation, respectively.

Article Snippet: The OPB and YPB (YY1 protein binding domain in the human EZH2 protein) peptides, as we previously reported [ ], were synthesized by the ChinaPeptides Co., Ltd. (Shanghai, China).

Techniques: Targeted Gene Expression, Protein-Protein interactions, Ubiquitin Proteomics

Journal: Redox Report : Communications in Free Radical Research

Article Title: Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone

doi: 10.1179/1351000215Y.0000000025

Figure Lengend Snippet: Time course of changes in the concentrations of edaravone (•) and 4-NO-edaravone (▪) when 1.0 mM edaravone was treated with 1.0 mM SIN-1 in 20 mM phosphate buffer (pH 7.4) containing 50% methanol and 50 µM DETAPAC under aerobic conditions at 37 °C. The inset figure shows changes in 4-NO2-edaravone (▴), 4-oxoedaravone (○), and OPB (□).

Article Snippet: A gift of 4-oxoedaravone, OPB, 4-NO-edaravone, and 4-NO 2 -edaravone from Mitsubishi Tanabe Pharma Corporation is gratefully acknowledged.

Techniques: